One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market ...

Researchers analyzed US-based phase 1-3 cancer treatment trials registered on ClinicalTrials.gov from 2017 to 2022.

Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment.

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $52.76 which represents a slight increase of $0.64 or 1.23% from the prior close of $52.12. The stock opened at ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Evotec announced in May of 2022 that the Company has further extended and expanded its partnership with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Big Pharma is in federal appeals court making the absurd argument that Medicare shouldn’t be able to negotiate drug prices, a ...

Bristol-Myers Squibb (BMY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from Leerink Partners maintained a Hold rating on ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede ...